{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:49Z","timestamp":1790375989255,"version":"4.1.0"},"reference-count":91,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01010","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T03:41:33Z","timestamp":1504064493000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas"],"prefix":"10.3389","volume":"8","author":[{"given":"Christian","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marie-Cardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin\u2019s lymphoma","volume":"59","author":"Molina","year":"2008","journal-title":"Annu Rev Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.4049\/jimmunol.1490027","article-title":"Translational medicine in action: anti-CD20 therapy in lymphoma","volume":"193","author":"Lim","year":"2014","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","article-title":"Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays","volume":"526","author":"Golay","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"B7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/978-3-319-07911-0_17","article-title":"Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer","volume":"382","author":"Bakema","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1124\/mol.114.092684","article-title":"Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies","volume":"86","author":"Taylor","year":"2014","journal-title":"Mol Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","article-title":"Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape","volume":"28","author":"Ferris","year":"2010","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjd.13832","article-title":"Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma task force study of 97 cases","volume":"173","author":"Klemke","year":"2015","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/jid.2014.356","article-title":"CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells","volume":"135","author":"Moins-Teisserenc","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2340\/00015555-2264","article-title":"Expression of CD164 on malignant T cells in Sezary syndrome","volume":"96","author":"Guenova","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/ajd.12349","article-title":"Mycosis fungoides and Sezary syndrome: current challenges in assessment, management and prognostic markers","volume":"57","author":"Hughes","year":"2016","journal-title":"Australas J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/JID.2015.360","article-title":"Expression of Sezary biomarkers in the blood of patients with erythrodermic mycosis fungoides","volume":"136","author":"Hurabielle","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2133.2009.09364.x","article-title":"Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sezary syndrome","volume":"162","author":"Bouaziz","year":"2010","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/jid.2010.404","article-title":"Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sezary syndrome patients","volume":"131","author":"Bensussan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1600-0625.2012.01489.x","article-title":"CD158k\/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides","volume":"21","author":"Ortonne","year":"2012","journal-title":"Exp Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jid.2016.01.038","article-title":"Evaluation of immunophenotypic and molecular biomarkers for Sezary syndrome using standard operating procedures: a multicenter study of 59 patients","volume":"136","author":"Boonk","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00251-015-0869-7","article-title":"The evolution of natural killer cell receptors","volume":"68","author":"Carrillo-Bustamante","year":"2016","journal-title":"Immunogenetics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s003359900961","article-title":"Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4","volume":"10","author":"Wende","year":"1999","journal-title":"Mamm Genome"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/0-387-24180-9_6","article-title":"Influence of KIR diversity on human immunity","volume":"560","author":"Parham","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"208ra145","DOI":"10.1126\/scitranslmed.3006702","article-title":"Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry","volume":"5","author":"Horowitz","year":"2013","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood-2008-05-156836","article-title":"The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells","volume":"113","author":"Brodin","year":"2009","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1472-6483(10)60574-3","article-title":"NK cells and surveillance in humans","volume":"16","author":"Schmitt","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"B32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/humupd\/dms015","article-title":"Extravillous trophoblast and decidual natural killer cells: a remodelling partnership","volume":"18","author":"Wallace","year":"2012","journal-title":"Hum Reprod Update"},{"key":"B33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1084\/jem.20041214","article-title":"Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success","volume":"200","author":"Hiby","year":"2004","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1002\/art.21395","article-title":"Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis","volume":"52","author":"Chan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.184.2.505","article-title":"The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58\/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer","volume":"184","author":"Pende","year":"1996","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.4049\/jimmunol.156.9.3098","article-title":"A human killer inhibitory receptor specific for HLA-A1,2","volume":"156","author":"Dohring","year":"1996","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/eji.200425089","article-title":"Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific","volume":"34","author":"Hansasuta","year":"2004","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"10160","DOI":"10.1073\/pnas.0913745107","article-title":"Peptide antagonism as a mechanism for NK cell activation","volume":"107","author":"Fadda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/art.10605","article-title":"Cell-surface expression and immune receptor recognition of HLA-B27 homodimers","volume":"46","author":"Kollnberger","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/eji.200635997","article-title":"Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide","volume":"37","author":"Kollnberger","year":"2007","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2009-12-256586","article-title":"A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2","volume":"116","author":"Sivori","year":"2010","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1182\/blood-2003-08-2820","article-title":"Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production","volume":"104","author":"Chalifour","year":"2004","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4049\/jimmunol.173.2.1179","article-title":"TLR9 is localized in the endoplasmic reticulum prior to stimulation","volume":"173","author":"Leifer","year":"2004","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.4049\/jimmunol.175.3.1636","article-title":"TLR7\/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production","volume":"175","author":"Hart","year":"2005","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/intimm\/dxn073","article-title":"Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC","volume":"20","author":"Marcenaro","year":"2008","journal-title":"Int Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/ijms17091433","article-title":"Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type","volume":"17","author":"Fabre","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/art.1780391028","article-title":"HLA-B associations of HLA-B27 negative ankylosing spondylitis: comment on the article by Yamaguchi et al","volume":"39","author":"Brown","year":"1996","journal-title":"Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1309\/05GFG3LY3VYCDMEY","article-title":"The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sezary syndrome","volume":"129","author":"Kelemen","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1365-2133.2008.08739.x","article-title":"The diagnosis of Sezary syndrome on peripheral blood by flow cytometry requires the use of multiple markers","volume":"159","author":"Klemke","year":"2008","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jaad.2011.06.014","article-title":"Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sezary syndrome","volume":"66","author":"Nagler","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B53","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.V96.9.2987","article-title":"Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma","volume":"96","author":"Delfau-Larue","year":"2000","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5411\/wji.v3.i1.1","article-title":"Natural killer reprogramming in cutaneous T-cell lymphomas: fact and hypotheses","volume":"3","author":"Schmitt","year":"2013","journal-title":"World J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1182\/blood-2001-12-0303","article-title":"Engagement of ILT2\/CD85j in Sezary syndrome cells inhibits their CD3\/TCR signaling","volume":"100","author":"Nikolova","year":"2002","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/blood.V97.5.1388","article-title":"CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor","volume":"97","author":"Bagot","year":"2001","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1074-7613(00)80135-1","article-title":"The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18","volume":"11","author":"Chapman","year":"1999","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.4049\/jimmunol.181.7.4507","article-title":"Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional","volume":"181","author":"Tang","year":"2008","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1084\/jem.20060028","article-title":"Reprogramming of CTLs into natural killer-like cells in celiac disease","volume":"203","author":"Meresse","year":"2006","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1172\/JCI115920","article-title":"Interleukin-7 is a growth factor for Sezary lymphoma cells","volume":"90","author":"Dalloul","year":"1992","journal-title":"J Clin Invest"},{"key":"B61","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood.V91.11.4331","article-title":"Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma","volume":"91","author":"Bagot","year":"1998","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V96.3.1056","article-title":"Functional characterization of an IL-7-dependent CD4(+)CD8alphaalpha(+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma","volume":"96","author":"Poszepczynska","year":"2000","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood-2002-09-2915","article-title":"Polymorphic expression of CD158k\/p140\/KIR3DL2 in Sezary patients","volume":"101","author":"Musette","year":"2003","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.0022-202X.2004.22326.x","article-title":"CD158k\/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome","volume":"122","author":"Poszepczynska-Guigne","year":"2004","journal-title":"J Invest Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2005-10-4239","article-title":"Significance of circulating T-cell clones in Sezary syndrome","volume":"107","author":"Ortonne","year":"2006","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.jid.5701013","article-title":"CD158K\/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sezary syndrome","volume":"128","author":"Ortonne","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/cyto.b.20395","article-title":"CD158k\/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry","volume":"74","author":"Bahler","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-16-3185","article-title":"Usefulness of KIR3DL2 to diagnose, follow-up and manage the treatment of Sezary syndrome patients","volume":"23","author":"Hurabielle","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1600-065X.2001.1810123.x","article-title":"Biology of T memory type 1 cells","volume":"181","author":"Anfossi","year":"2001","journal-title":"Immunol Rev"},{"key":"B71","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nri1306","article-title":"Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future","volume":"4","author":"Vivier","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.4049\/jimmunol.173.12.7223","article-title":"Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells","volume":"173","author":"Anfossi","year":"2004","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/0008-5472.CAN-08-4631","article-title":"Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death","volume":"69","author":"Klemke","year":"2009","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2014-09-598995","article-title":"KIR3DL2 is a coinhibitory receptor on Sezary syndrome malignant T cells that promotes resistance to activation-induced cell death","volume":"124","author":"Thonnart","year":"2014","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/jid.2014.286","article-title":"KIR3DL2\/CpG ODN interaction mediates Sezary syndrome malignant T cell apoptosis","volume":"135","author":"Ghazi","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/bjd.14626","article-title":"KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma","volume":"175","author":"Battistella","year":"2016","journal-title":"Br J Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1158\/0008-5472.CAN-14-1456","article-title":"IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma","volume":"74","author":"Marie-Cardine","year":"2014","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e1022306","DOI":"10.1080\/2162402X.2015.1022306","article-title":"A novel targeted immunotherapy for CTCL is on its way: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies","volume":"4","author":"Sicard","year":"2015","journal-title":"Oncoimmunology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2437_31","article-title":"Phase I study of IPH4102, anti-KIR3DL2 mab, in relapsed\/refractory cutaneous T-cell lymphomas (CTCL): dose-escalation safety, biomarker and clinical activity results","volume":"35","author":"Bagot","year":"2017","journal-title":"Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"606","DOI":"10.2340\/00015555-2027","article-title":"Stevens-Johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient","volume":"95","author":"Honda","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and Sezary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T09:21:32Z","timestamp":1692955292000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,30]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2017.01010"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01010","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,30]]},"article-number":"1010"}}